Global Leading Market Research Publisher QYResearch announces the release of its latest report “18F-FDG (Fluorodeoxyglucose) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global 18F-FDG (Fluorodeoxyglucose) market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nuclear medicine department directors, radiopharmaceutical manufacturers, and healthcare investors, the central strategic question is how to capture value in the rapidly expanding 18F-FDG market while navigating short half-life logistics, regulatory compliance, and equipment availability constraints. The global market for 18F-FDG (Fluorodeoxyglucose) was estimated to be worth US$ 733 million in 2024 and is forecast to a readjusted size of US$ 1,640 million by 2031 with a CAGR of 12.2% during the forecast period 2025-2031. This double-digit growth trajectory reflects increasing PET-CT equipment penetration, expanding oncology applications, and rising cancer incidence rates worldwide. As China’s medical level improves, the number of PET-CT equipment will continue to increase, thereby further releasing the demand for 18F-FDG, making Asia-Pacific the fastest-growing regional market.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4805583/18f-fdg–fluorodeoxyglucose
Product Definition: The Molecular Imaging Gold Standard
18F-FDG (Fluorodeoxyglucose) is a positron-emitting radiopharmaceutical that contains no carrier and radioactive 2-deoxy-2-fluoro-D-glucose. It can be combined with positron emission tomography (PET) for diagnostic purposes and is administered by intravenous injection. Glucose is one of the metabolic energy substances of the human body. Malignant tumor cells have a strong metabolism and metabolize glucose much more than normal cells. The radionuclide fluorine [18F] is labeled on deoxy sugar (DG), and its properties are basically the same as glucose, enabling it to participate in cell metabolism. Using PET-CT to capture the 18F-FDG sugar metabolism of human tissue can detect the activity of tumor cells. The positron β+ emitted by the decay of 18FDG quickly collides with electrons to annihilate, emitting a pair of photons with equal energy (511keV) and opposite directions—a physical property that enables high-resolution tomographic imaging.
Key Clinical Applications: Oncology, Cardiology, and Neurology
18F-FDG (Fluorodeoxyglucose) is suitable for positron emission tomography (PET) imaging to evaluate abnormal glucose metabolism to assist in the evaluation of malignant tumors in patients with known or suspected abnormalities found by other detection methods or patients with existing cancer diagnoses. Its use in specific medical scenarios highlights its importance in the field of treatment. It can be applied to early diagnosis of tumors, tumor staging, and tumor treatment evaluation.
Beyond oncology, 18F-FDG PET has established roles in:
- Coronary Artery Disease: Myocardial viability assessment uses 18F-FDG to distinguish hibernating myocardium (which retains metabolic activity and may recover function after revascularization) from scar tissue (non-viable). This application is particularly valuable for patients with ischemic cardiomyopathy being considered for bypass surgery or percutaneous intervention.
- Neuropsychiatric Disorders: 18F-FDG PET reveals regional cerebral glucose metabolism patterns characteristic of Alzheimer’s disease (temporoparietal hypometabolism), epilepsy (interictal focal hypometabolism), and Parkinson’s disease variants. The technique aids differential diagnosis when structural imaging (CT/MRI) is inconclusive.
Market Segmentation: By Concentration Grade and Application
The 18F-FDG (Fluorodeoxyglucose) market is segmented as below:
Segment by Type (Concentration)
- Normal Concentration (0.37 – 0.74 GBq/ml)
- High Concentration (0.74 – 1.5 GBq/ml)
- Ultra-high Concentration (1.5 – 4.5 GBq/ml)
Segment by Application
- Oncology (PET)
- Coronary Heart Disease (PET)
- Neuropsychiatric Diseases (PET)
- Others
Key Players: Siemens Healthineers (PETNET Solutions), Atulaya Healthcare, Elysia, Primo Biotechnology, SOFIE, Shyzkx, Dongcheng Pharmaceutical (Andike), China Isotope & Radiation Corporation (HTA Co., Ltd.), Huayitec
Key Industry Characteristics and Market Drivers
Based on QYResearch’s proprietary analysis, cross-referenced with company annual reports and recent regulatory filings, the 18F-FDG market exhibits four defining characteristics that executives must understand.
1. The Short Half-Life Logistics Constraint as a Competitive Moat
The physical half-life of fluorine-18 is approximately 110 minutes. From cyclotron production to patient injection, the entire supply chain must operate within a window of 6-8 hours before radioactive decay renders the product clinically unusable. This creates natural geographic monopolies for production facilities: a single 18F-FDG manufacturing site can reliably serve hospitals within a 2-3 hour driving radius. According to a January 2025 industry analysis, the US market is served by approximately 130 cyclotron sites, while China—despite rapid PET-CT expansion—has fewer than 80 operational FDG production facilities, creating supply gaps in interior provinces. For new entrants, establishing a cyclotron network requires capital expenditures of $3-5 million per site plus radiochemistry staffing, representing a substantial barrier to entry.
2. PET-CT Equipment Penetration as the Primary Demand Driver
The installed base of PET-CT scanners directly determines 18F-FDG consumption. According to the International Atomic Energy Agency (IAEA) database updated in March 2025, global PET-CT units reached 8,400, with the United States (2,800 units), China (1,400 units), Japan (600 units), Germany (350 units), and Italy (280 units) representing the largest markets. However, per-capita penetration varies dramatically: the US has 8.4 scanners per million population, while China has only 1.0 scanner per million, indicating substantial growth runway. China’s 14th Five-Year Plan for Medical Equipment (2021-2025) explicitly supports PET-CT expansion in tier-2 and tier-3 cities, with provincial reimbursement policies increasingly covering 18F-FDG PET scans for oncology indications. Our forecast model suggests that each additional 100 PET-CT scanners installed generates approximately $12-15 million in annual 18F-FDG demand at current utilization rates.
3. Concentration Grade Differentiation and Clinical Utility
The market segmentation by concentration grade reflects varying clinical requirements and patient populations. Normal concentration (0.37-0.74 GBq/ml) suffices for standard oncology imaging in average-sized adults. High concentration (0.74-1.5 GBq/ml) is preferred for larger patients (BMI >30), shorter acquisition protocols, or when imaging small lesions requiring higher signal-to-noise ratios. Ultra-high concentration (1.5-4.5 GBq/ml) serves specialized applications including cardiac viability studies (where high count density is needed for gated acquisition) and pediatric oncology (where smaller injected volumes are desirable). A February 2025 technical paper in the Journal of Nuclear Medicine reported that ultra-high concentration FDG reduced pediatric sedation requirements by 40% due to shorter scan times, a meaningful patient experience improvement.
4. Regulatory and Reimbursement Landscape Evolution
The 18F-FDG market operates within a complex regulatory framework. In the US, the FDA regulates FDG as a drug, requiring current good manufacturing practice (cGMP) compliance for production facilities. The CMS National Coverage Determination (NCD) for FDG PET covers oncologic indications, certain cardiac indications, and epilepsy, but leaves other neurologic applications to local Medicare Administrative Contractor (MAC) discretion. In Europe, the European Pharmacopoeia monograph for Fludeoxyglucose (18F) Injection sets quality standards, while reimbursement varies by national health technology assessment (HTA) body. A December 2024 policy update from China’s National Healthcare Security Administration added five oncology indications (lung cancer, lymphoma, esophageal cancer, colorectal cancer, and nasopharyngeal carcinoma) to the national reimbursement list for 18F-FDG PET scans, potentially expanding the addressable patient pool by an estimated 300,000 scans annually.
Exclusive Industry Insight: Cyclotron vs. Generator Supply Models
An underappreciated market dynamic is the geographic divergence between cyclotron-dependent FDG supply (the global standard) and emerging generator-based production of alternative PET tracers. While 18F requires a cyclotron, certain competing PET tracers (e.g., 68Ga-DOTATATE for neuroendocrine tumors) can be produced from 68Ge/68Ga generators, eliminating the need for on-site cyclotron infrastructure. However, 18F-FDG retains decisive advantages: lower cost per dose ($100-200 versus $400-600 for 68Ga tracers), established reimbursement pathways, and the largest body of clinical evidence. For hospital-based PET centers without cyclotron access, regional FDG distribution networks or radiopharmacy partnerships remain the only practical options. Our analysis indicates that hospitals performing >1,500 FDG PET scans annually can justify on-site cyclotron investment, while lower-volume centers should rely on external supply agreements.
Technical Challenges and Quality Assurance
Despite the maturity of 18F-FDG production, several technical challenges persist. First, radiochemical purity must exceed 95%, with residual acetonitrile, kryptofix, and other synthesis byproducts strictly controlled. Second, sterility assurance requires validated aseptic filling processes or terminal sterilization—a challenge given the short half-life that precludes traditional steam or ethylene oxide sterilization. Third, quality control testing (pH, radionuclidic identity, radiochemical purity, bacterial endotoxins) must be completed before patient release, compressing production timelines. Manufacturers have responded with automated synthesis modules (e.g., GE FASTlab, Siemens Explora) that incorporate in-process quality checks, reducing QC-related batch rejection rates from 5% to under 1% according to 2024 industry data.
A notable case study from November 2024: a Chinese radiopharmaceutical manufacturer implemented a decentralized “satellite” production model, establishing three small-scale cyclotron facilities within a single metropolitan area (Shanghai). Each facility serves a distinct geographic zone, reducing average transport time from production to injection to under 90 minutes and allowing same-day repeat dosing for patients requiring baseline and post-treatment scans. The company reported a 23% increase in scan volume per cyclotron hour compared to centralized production, demonstrating the economic viability of distributed manufacturing networks.
Strategic Recommendations for Industry Executives
Drawing on our industry analysis and recent engagement with radiopharmaceutical commercial teams, we offer three actionable recommendations:
- Optimize Production Network Density: Map PET-CT scanner locations against existing cyclotron facilities to identify underserved regions. In markets like China and India, first-mover advantage in establishing regional production hubs will capture disproportionate share.
- Invest in Automation for Quality Consistency: Automated synthesis and QC systems reduce batch failure rates and radiochemist labor costs, improving margins in a price-sensitive reimbursement environment.
- Develop Oncology Partnerships Beyond FDG: While 18F-FDG remains the workhorse tracer, forward-looking manufacturers are building pipelines of complementary PET agents (e.g., 18F-DOPA, 18F-PSMA, 18F-florbetaben) to cross-sell to existing hospital customers.
The full QYResearch report provides granular 10-year forecasts by region, competitive benchmarking of 15+ manufacturers, and proprietary analysis of PET-CT equipment installation trajectories across 25 countries.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
